Research programme: mGLUR1/5 antagonists - Allergan/Gedeon Richter

Drug Profile

Research programme: mGLUR1/5 antagonists - Allergan/Gedeon Richter

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Gedeon Richter
  • Developer Allergan; Gedeon Richter
  • Class
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists; Metabotropic glutamate receptor type 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; CNS disorders; Major depressive disorder

Most Recent Events

  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Anxiety disorders presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008)
  • 01 Dec 2005 Preclinical trials in Anxiety disorders in Hungary and USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top